Says: Sara Kovač
U.S. Pfizer and its German partner BioNTech said Thursday that the latest data from clinical trials in the third phase show that the covid-19 vaccine they developed in collaboration is very effective in fighting the South African version of the virus. Pfizer said in a statement that new data from South Africa showed 100 percent effectiveness of the vaccine, despite the prevalence of the rapidly spreading version of the B.1.351 virus.
The findings from the third phase of the study come to light at a time when countries are particularly concerned about the efficacy of existing vaccines against new, more portable versions of the coronavirus. There are concerns about how to completely control the disease as the virus continues to mutate.
“The data also provide the first clinical results that the vaccine can effectively protect against current versions of the virus currently circulating, a key factor in achieving herd immunity and combating this pandemic worldwide,” BioNTech CEO told Russia Today. Ugur Sahin.
Although the company highlights the positive elements of the clinical trials, it should be noted that only 800 individuals were included in the study section in South Africa, which means that the results could be argued to be limited. Extensive research, in addition to findings on the efficacy of vaccines against virus variants, showed that Pfizer was 91.3% effective against coronavirus and 100% effective in 46,307 study participants with severe disease.
Pfizer-BioNTech is used worldwide. It has also been issued a use permit by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the UK Medicines and Health Products Regulatory Agency (MHRA).